0001209191-18-058222.txt : 20181113
0001209191-18-058222.hdr.sgml : 20181113
20181113161540
ACCESSION NUMBER: 0001209191-18-058222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181108
FILED AS OF DATE: 20181113
DATE AS OF CHANGE: 20181113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bozigian Haig P.
CENTRAL INDEX KEY: 0001423837
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 181178137
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-08
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423837
Bozigian Haig P.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Development Officer
Common Stock
2018-11-08
4
M
0
19501
8.66
A
155498
D
Common Stock
2018-11-08
4
S
0
19501
110.00
D
135997
D
Common Stock
2018-11-08
4
M
0
16794
8.65
A
152791
D
Common Stock
2018-11-08
4
S
0
16794
110.00
D
135997
D
Non-Qualified Stock Option
8.66
2018-11-08
4
M
0
19501
8.66
A
2022-01-12
Common Stock
19501
34547
D
Non-Qualified Stock Option
8.65
2018-11-08
4
M
0
16794
8.65
A
2023-01-10
Common Stock
16794
34376
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Option granted January 12, 2012 and vested monthly over four years.
Option granted January 10, 2013 and vested monthly over four years.
/s/ Darin Lippoldt, Attorney-in-Fact
2018-11-13